SCHEMBL1765017

SCHEMBL1765017

O=C1CN(C(=O)c2cc(-c3ccc(F)c(F)c3)n(-c3cccc(Cl)c3)n2)CN1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPP1CA P62136 1/20 0.49
MALT1 Q9UDY8 2/20 0.45
CCKAR P32238 1/20 0.44
PTGS2 P35354 2/20 0.44
PTGS1 P23219 1/20 0.44
MGLL Q99685 3/20 0.44
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CHRNA7 P36544 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SLC5A1 P13866 2/20 0.40
MARS1 P56192 1/20 0.40
NTRK1 P04629 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1765330 0.93 PPP1CA (0.48) PPP1CAMALT1CCKARPTGS2PTGS1
SCHEMBL1765318 0.92 PPP1CA (0.47) PPP1CAMALT1CCKARPTGS2PTGS1
SCHEMBL1765402 0.91 PTGS2 (0.52) PPP1CAMALT1CCKARPTGS2PTGS1
SCHEMBL1765086 0.90 PPP1CA (0.45) PPP1CAMALT1CCKARPTGS2PTGS1
SCHEMBL1765529 0.89 PPP1CA (0.47) PPP1CAMALT1CCKARPTGS2PTGS1
SCHEMBL1765351 0.88 PPP1CA (0.46) PPP1CAMALT1CCKARPTGS2PTGS1
SCHEMBL1765055 0.87 MGLL (0.54) PPP1CAMALT1CCKARPTGS2PTGS1
SCHEMBL1765303 0.86 NTRK1 (0.43) PPP1CAMALT1CCKARPTGS2PTGS1
SCHEMBL14995333 0.86 PPP1CA (0.47) PPP1CAMALT1CCKARPTGS2PTGS1
SCHEMBL1765011 0.86 PTGS2 (0.52) PPP1CAMALT1CCKARPTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
WO-2009115213-A1 (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES AICURIS GMBH & CO. KG (DE) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE TPMT, PAICS, THPO PPP1CA 1664/4885MALT1 70/4885CCKAR 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.